Q-omics provides the consensus-scored MIR1245A profile across patient tissues and cancer cell-line models. MIR1245A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR1245A is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, MIR1245A RNA expression shows 8,693 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where MIR1245A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1245A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1245A survival associations across molecular data types. MIR1245A RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1245A RNA expression–survival associations across cancer types. High MIR1245A expression shows unfavorable associations in KIRC, KIRP, KICH, LGG and THCA, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR1245A RNA expression.
This table summarizes MIR1245A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1245A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1245A shows lower tumor expression in BRCA, UCEC and THCA and higher tumor expression in LUAD, HNSC and STAD. The LUAD box plot shows higher MIR1245A RNA expression in tumor versus normal tissue (log2 FC = +0.391, t-test p = .008).
This table shows molecular features associated with MIR1245A in patient tissues and cancer cell lines. In patient samples, MIR1245A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
